ANKIAL Pharma

ANKIAL Pharma is a biotech-Pharma start-up company that is developing a drug to treat hypertrophic cardiomyopathy (HCM), a heart disease that affects 20 million patients worldwide. The drug ANK0121 (patented by INSERM/Bordeaux Hospital and University) acts on mitochondria, the powerplant of the heart. This technology promotes mitochondrial recycling to improve heart bioenergetics and prevent hypertrophic cardiomyopathy in various in vivo models of HCM. ANKIAL operates from the preclinical phase to the marketing authorization. The team includes 5 founders. The CEO is an international expert in mitochondrial pharmacology, the COO has experience in biotech company management, the CTO has 25 years of expertise in the pharmaceutical industry sector (cardiology drugs), the CMO is a member of the Academy of Medicine and has directed clinical trials, and the CFO is a certified accountant/auditor; he defines the financial strategy of many biotech pharma companies. Our ANK0121 technology is patented, formulated and tested in vivo and its usability is validated. Current stage of ANKIAL is fund raising to advance regulatory toxicity analysis and complete the IND request.

Site web

ankialpharma.com

Lien externe pour ANKIAL Pharma

Secteur

Fabrication de produits pharmaceutiques

Taille de l’entreprise

2-10 employés

Siège social

Bordeaux, Nouvelle-Aquitaine

Type

Partenariat

Fondée en

2023

Domaines

pharma, heart, mitochondria, cardiomyopathy, rasopathy, mitochondrial diseases et bioenergetics